Implications of the Iressa® Survival Evaluation in Lung Cancer Trial and the future of gefitinib

Chandra Belani, Sakkaraiappan Ramalingam

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)203-204
Number of pages2
JournalClinical Lung Cancer
Volume6
Issue number4
StatePublished - Jan 2005

Fingerprint

Drug Dose Response Relationship
Quinazolines
Survival Analysis
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Lung Neoplasms
Randomized Controlled Trials
gefitinib

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

@article{1872ea61133b40d48b95ab9135b51fa5,
title = "Implications of the Iressa{\circledR} Survival Evaluation in Lung Cancer Trial and the future of gefitinib",
author = "Chandra Belani and Sakkaraiappan Ramalingam",
year = "2005",
month = "1",
language = "English (US)",
volume = "6",
pages = "203--204",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

Implications of the Iressa® Survival Evaluation in Lung Cancer Trial and the future of gefitinib. / Belani, Chandra; Ramalingam, Sakkaraiappan.

In: Clinical Lung Cancer, Vol. 6, No. 4, 01.2005, p. 203-204.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Implications of the Iressa® Survival Evaluation in Lung Cancer Trial and the future of gefitinib

AU - Belani, Chandra

AU - Ramalingam, Sakkaraiappan

PY - 2005/1

Y1 - 2005/1

UR - http://www.scopus.com/inward/record.url?scp=14644422191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644422191&partnerID=8YFLogxK

M3 - Editorial

C2 - 15694010

AN - SCOPUS:14644422191

VL - 6

SP - 203

EP - 204

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -